Entities

Jesper Buch served on the final Vækstfonden board from August31,2022 through March31,2023. The statutory2022 report publishes his original portrait and lists entrepreneurial/investment affiliations including GuerillaCapital, JesperBuchHolding, Reboot and multiple growth-company boards. His separate existing EIFO role is retained, with no personal investment inferred from governance.

Martin Nørkjær Larsen, also published as Martin Larsen, is vice chairman of Danske Bank’s Board of Directors and chairs its Nomination Committee. He is CFO of A.P. Møller Holding and has experience in finance, capital planning, debt and equity markets, and corporate governance. His earlier career includes financial planning at Maersk Group and CFO responsibilities at Maersk Supply Service. He studied economics and finance at Warwick and Copenhagen and completed an MBA programme at Columbia and London Business School. The bank’s own current CV explicitly identifies his EIFO board membership, confirming the identity of the existing MartinLarsen record; that affiliation is preserved.

Scale Capital is a Copenhagen-based venture investment firm backing early-stage European technology companies, especially Nordic B2B businesses. Its strategy spans enterprise software, AI and computing infrastructure, industrial robotics, energy and climate technology, and defence/security, with a focus on helping European companies grow internationally while retaining their technology and ownership in Europe. It combines investment staff with venture partners in US and European technology hubs. The firm’s current team biography dates its founding to2012. Its own FundIII key-information document names the legal manager Scale Capital Management ApS and the Danish regulator registration FT23177; earlier materials name SC Management ApS for older funds, which are separate legal entities rather than interchangeable fund IDs. Its EUR12m Six Robotics seed-round participation is explicitly confirmed by the company and its own portfolio page. Own2026 newsletter attributes the Six investment to FundIII. FundIII’s launch/close occurred before the requested October2023 window; no new in-window fund close is proved.

Published on Scale’s contact page, but absent from its updated current team directory. Current employment is unverified; the listed contact role is preserved with this explicit qualification.

Published on Scale’s contact page, but absent from its updated current team directory. Current employment is unverified; the listed contact role is preserved with this explicit qualification.

HICO Investment Group is a Singapore-based private investment group focused on maritime transport, logistics, energy transition and technology used in those industries, with additional hospitality interests. It invests directly in venture-stage and established growth businesses and works with their management teams on development and expansion. Its broader investment office also manages public markets, marketable alternatives, private equity and venture exposure. The group has offices in Singapore and London. Its own public statements confirm investment in Kraken Technology Group’s July2026 SeriesB and earlier financing rounds. The Hartnoll group uses hico.one and is distinct from the SK Networks-backed Silicon Valley HICO Ventures at hico.vc. UK HICO Ventures Limited13943684 is a separately registered Hartnoll-directed entity; primary materials describe HICO Ventures as an adviser to HICO Asset Management Private Ltd, and the precise legal subscriber for the Kraken round is not disclosed. No newly raised fund vehicle or fund commitment amount is established.

Named in HICO Investment Group’s own public employee list. His exact formal title is not exposed in the primary public directory; secondary-directory titles are not asserted.

Leads development of HICO’s private-equity and venture-capital investment sleeve, as described in CIO Ellen Ellison’s current public team announcement.

Leads the investment office’s public and marketable-alternative investments. Her own September2026 post confirms her CIO role and describes the current HICO team. Earlier own2022 announcement identifies HICO Ventures Ltd as adviser to HICO Asset Management Private Ltd; those legal entities are not collapsed into one.

Named in HICO Investment Group’s own public employee list; his own professional profile confirms the HICO affiliation. A specific current title is not exposed in the primary public directory.

Joined HICO’s London investment office in September2026 after six years at Brown University’s Investment Office. Supports public markets and marketable alternatives and development of the private-equity and venture sleeve; exact formal title undisclosed.

Carlos von Bonhorst is a strategic adviser to 3B Future Health Fund. He is a physician with experience in pharmaceutical development, senior management and technology transfer, including former Helsinn corporate-development leadership. His advisory experience covers research and innovation institutions in Europe.

Paolo Paoletti is a strategic adviser to 3B Future Health Fund with pharmaceutical research, clinical-development and commercialization experience. His published career includes GSK oncology leadership, Lilly drug development and founding GammaDelta Therapeutics. Historical operating titles in the biography are not asserted as current independent appointments.

Sandra van Essche is the corporate-affairs adviser to 3B Future Health Fund. Her professional experience includes corporate and securities transactions, private equity, IPOs and mergers, with prior legal roles at Chadbourne & Parke, PanAmSat and GLG Partners. The advisory role is distinguished from an investment general-partner position.

Karin Hehenberger is a strategic adviser to 3B Future Health Fund. Her career spans life-science management, healthcare investment and patient entrepreneurship, including the creation of Lyfebulb and prior roles at J&J, JDRF and McKinsey. She holds medical and doctoral qualifications. Separate operating affiliations are not fund-management appointments.

Alessandro Santoboni is managing director and general partner of 3B Future Health Fund. He progressed through investment analysis, due diligence and investor relations before taking responsibility for strategy and portfolio development. He previously founded a technology business and studied economics and business administration at Università Cattolica del Sacro Cuore.

Francesco Giavatto is chief financial officer and general partner of 3B Future Health Fund. Its biography dates his CFO board appointment to 2020 and describes prior senior banking work at Bank of Ireland, UBS, ING and Banque Internationale Luxembourg. He studied business economics and co-founded a Swiss family office.

Francesco Granata is a strategic adviser and general partner at 3B Future Health Fund, which he joined in 2016. His career spans pharmaceutical research, commercial leadership and company governance, including former senior roles at Biogen, Pfizer and Schering-Plough. He is a physician with a cardiology specialization.

Riccardo Braglia leads 3B Future Health Fund as chairman and general partner. He established its predecessor fund with Helsinn support in 2016 and brings pharmaceutical development and commercialization experience. The fund’s own biography identifies his Helsinn executive-chairman affiliation and Bocconi business education.

DrugBank develops a biomedical knowledge platform for pharmaceutical research and clinical decision support. Its curated knowledge graph connects drugs, targets, diseases, clinical trials and commercial information. Biopharma OS lets research and portfolio teams search and analyze these relationships, while APIs, data products and an MCP interface supply structured information to software and AI agents. Its Clinical Intelligence API supports applications such as medication-interaction checking. DrugBank combines scientific curation with AI-assisted data processing; it supplies research and healthcare infrastructure rather than developing its own medicines.

Interventional neuroradiologist and scientist whose research includes stroke treatment and flow-diverting stents for brain aneurysms.

Neuroscientist and Eularis founder whose work connects pharmaceutical strategy with applied AI.

Life sciences executive with prior CEO roles at ObsEva, Petra Pharma, Acucela, Sangart and BioPartners.

Pharmaceutical commercialization and business-development executive with prior leadership at ObsEva, Petra Pharma and Sangart.

Bioinformatics specialist and DrugBank co-founder who helped build DrugBank and the Human Metabolome Database.

Human-resources executive with technology and biotechnology experience; holds HR and business qualifications from Suffolk University and Providence College.

Life-sciences investor, also published as Jackie Fok, with experience at SoftBank Vision Fund, IP Group and AstraZeneca.

Life sciences and biomedical-data executive with prior leadership at Clarivate and GlobalData. Appointed DrugBank CEO effective October 6, 2025.

Oligonucleotide scientist and consultant with prior therapeutic-RNA research leadership at GlaxoSmithKline and AstraZeneca.

Stroke-imaging and interventional-neuroradiology researcher associated with the University of Calgary and Calgary Stroke Program.

Precision-health and life-sciences company operator; DrugBank identifies him as its executive chair and separately as CEO of Marketech Solutions.

DrugBank co-founder, published as Mike Wilson in its current roster; helped develop the University of Alberta drug database and now directs product development and AI capabilities.

Pharmaceutical biometrics and data-science executive whose experience includes AI and machine-learning deployment.

Stroke neurologist and clinical trialist with clinical-epidemiology training and cerebrovascular research experience.

Physician and genomics researcher who previously led systems biology at Decibel Therapeutics; develops sequencing and cellular-technology capabilities at Deep Genomics.

Interventional neuroradiologist specializing in imaging and minimally invasive treatment of vascular disorders of the brain and spine.

Biotechnology entrepreneur and investor, also known as Ness Bermingham; founded Intellia, Korro Bio and Liberate Bio.

Drug-discovery scientist with prior research leadership at Genentech and 23andMe and academic work in neuroscience.

Medicinal-chemistry and drug-discovery leader with prior research leadership at Takeda, Stoke Therapeutics, AstraZeneca and Roche.

Genetic-medicine scientist formerly at Ginkgo Bioworks; leads Deep Genomics’ platform-biology and therapeutic-discovery activities.

Named as DrugBank’s Director, People in its October 2025 leadership announcement.

Pharmaceutical research, data and digital-technology leader; leads DrugBank’s advisory board and serves on its board of directors.

Genetic-medicine scientist and adviser, formerly President and CSO of Chroma Medicine and CTO of Editas Medicine.

Neurosurgeon and interventional neuroradiologist specializing in minimally invasive treatment of brain and spinal vascular disorders.

Biotechnology finance executive, published as William D. “Chip” Baird; prior CFO experience at bluebird bio, Amicus and PTC. Deep Genomics’ July 2026 announcement identifies him as non-executive director and audit committee chair.

Medical-device entrepreneur and inventor who co-founded Angiotech and founded Canary Medical; focuses on drug-eluting and sensor-equipped implants. Published as Dr William (Bill) Hunter in the manager advisory directory. Physician and medical-device inventor, co-founder of Angiotech and founder of Canary Medical. His work covers drug-eluting and sensor-equipped implants. Holds UBC medicine and science degrees and a McGill science degree; old Cardiome executive titles are historical career context.

Sandra Wilikens is publicly documented as Board Director — Belgium NV (qualified legal subsidiary) within the BNP Paribas Fortis Private Equity platform. This specifically scoped public affiliation is distinct from a personal cash investment or a parentbank investment check.

Annegreet De Smedt is publicly documented as Board Director — Belgium NV (qualified legal subsidiary) within the BNP Paribas Fortis Private Equity platform. This specifically scoped public affiliation is distinct from a personal cash investment or a parentbank investment check.

Eline Byl is publicly documented as Life Sciences Investment Associate within the BNP Paribas Fortis Private Equity platform. This specifically scoped public affiliation is distinct from a personal cash investment or a parentbank investment check.

Emiel De Saeytyd is publicly documented as Investment Associate within the BNP Paribas Fortis Private Equity platform. This specifically scoped public affiliation is distinct from a personal cash investment or a parentbank investment check.

Frank Claeys is publicly documented as Board Director — Belgium NV (qualified legal subsidiary) within the BNP Paribas Fortis Private Equity platform. This specifically scoped public affiliation is distinct from a personal cash investment or a parentbank investment check.

Julie De Schrijver is publicly documented as Investment Analyst within the BNP Paribas Fortis Private Equity platform. This specifically scoped public affiliation is distinct from a personal cash investment or a parentbank investment check.

Laurence Grimard is publicly documented as Performance Analyst within the BNP Paribas Fortis Private Equity platform. This specifically scoped public affiliation is distinct from a personal cash investment or a parentbank investment check.

Sophie Goffart is publicly documented as Personal Assistant within the BNP Paribas Fortis Private Equity platform. This specifically scoped public affiliation is distinct from a personal cash investment or a parentbank investment check.

Stéphane Vermeire is publicly documented as Board Director — Belgium NV (qualified legal subsidiary) within the BNP Paribas Fortis Private Equity platform. This specifically scoped public affiliation is distinct from a personal cash investment or a parentbank investment check.

Sylvana Locurto is publicly documented as Administrative Officer within the BNP Paribas Fortis Private Equity platform. This specifically scoped public affiliation is distinct from a personal cash investment or a parentbank investment check.

Anne Wautier is publicly documented as Investment Manager within the BNP Paribas Fortis Private Equity platform. This specifically scoped public affiliation is distinct from a personal cash investment or a parentbank investment check.

Koen Broothaerts is publicly documented as Investment Director within the BNP Paribas Fortis Private Equity platform. This specifically scoped public affiliation is distinct from a personal cash investment or a parentbank investment check.

Mark Gevens is currently an Investment Director at BNP Paribas Fortis Private Equity. His original own biography records joining in2012 after roles at Exane BNP Paribas, Fortis and Petercam, with a VUB commercial-engineering degree.

Patty Terryn is publicly documented as Commercial Director within the BNP Paribas Fortis Private Equity platform. This specifically scoped public affiliation is distinct from a personal cash investment or a parentbank investment check. Theodorus publishes Patty Terryn with the following specifically scoped affiliation: Investment Committee member — BNP Paribas (committee/LP representative affiliation, not an employment claim); LPAC member — BNP Paribas (committee/LP representative affiliation, not an employment claim). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date.

Renaat Denolf is COO of BNP Paribas Fortis Private Equity. The own original team biography says he joined in2005 after roles at the European Commission and McKinsey, and studied commercial engineering at KU Leuven.

Sofie Vermeulen is publicly documented as Investment Manager within the BNP Paribas Fortis Private Equity platform. This specifically scoped public affiliation is distinct from a personal cash investment or a parentbank investment check.

Steven Van Droogenbroeck is publicly documented as Investment Manager within the BNP Paribas Fortis Private Equity platform. This specifically scoped public affiliation is distinct from a personal cash investment or a parentbank investment check.

Sven Vermeulen is publicly documented as Investment Manager within the BNP Paribas Fortis Private Equity platform. This specifically scoped public affiliation is distinct from a personal cash investment or a parentbank investment check.

Toon Frans is publicly documented as Investment Associate within the BNP Paribas Fortis Private Equity platform. This specifically scoped public affiliation is distinct from a personal cash investment or a parentbank investment check.

BNP Paribas Fortis Private Equity is the Belgian bank group’s long-term institutional private-equity investing platform. It invests directly through minority equity and mezzanine financing and indirectly through private-equity funds, focusing on Belgian companies across sectors apart from real estate. Its own current policy describes indicativeEUR1M–50M tickets, typicallyEUR3M–15M; these are policy ranges rather than actual company checks. It explicitly operates without a closed-end fund timetable, supporting patient investment horizons rather than a newly raised limited-life LP fund. The principal Belgian investment holding, BNP Paribas Fortis Private Equity Belgium NV, is an active separate legal subsidiary BE0421.883.286, incorporated September16,1981; the bank’s historical brochure dates private-equity operations from1982. Current official KBO and GLEIF records verify that legal identity and registered Warandeberg3 Brussels address. The holding’s six statutory directors are Raf Moons, Renaat Denolf, Frank Claeys, Annegreet De Smedt, Stéphane Vermeire and Sandra Wilikens. Related BNP Paribas Fortis Private Equity Management NV BE0438.091.788 was incorporated July25,1989 and absorbed Fortis Private Equity Venture Belgium BE0431.044.244 inSeptember2014; it remains a distinct governance/service entity. The platform description qualifies both legal units rather than claiming that every broadly named historical company check belongs to one particular subscribing subsidiary. BNP Paribas parentInvestor and other Fortis entities remain separate; no parentbank cash check is duplicated. The current operating directory publishes16 named investment and support people headed by Raf Moons, with Renaat Denolf as COO. Four further source-confirmed holding directors bring the combined scoped public roster to20 unique people. Public titles and subsidiary-specific board positions are retained;20 is not a legal-entity employee headcount. Raf’s existing authentic portrait, biography and GFF permanent-representative roles are preserved. Three further genuine portraits are recovered: Renaat and Mark from the bank’s original historical team PDF, with current titles independently verified, and Sandra from the group’s own current named leadership page. Sixteen people lack a recoverable original portrait: the current bank directory’s16 direct asset paths return denied or unavailable content, so no artificial images or anonymous silhouettes are used. The bank’s own current portfolio and historical original credentials document reMYND equity investments inSeptember2009 andMay2016. Issuer sources separately name this private-equity platform in the actualDecember2018 SeriesB andJanuary2021 second close; individual check amounts and exact2016/2018/2021 subscribing subsidiaries are unpublished. The official2009 ARKimedes-Fonds report identifies Fortis Private Equity Arkimedes as the older vehicle and reports EUR750,000 cumulative investments through December31,2009; this is not assigned as a September2009 event ticket. These direct company equity events differ from licensing or clinical partnerships. The platform and PMV also act as advisory/service providers for Belgian Growth Fund structures; BGF I’s actual312M final commitment corpus and BGF II’s EUR247.5M committed corpus at its second close at the end ofDecember2025, reportedJanuary14,2026 with fundraising still open belong to those separately constituted funds, not to new capital raised by this own-capital platform. BGF II is a distinct registered self-managed AICB with separate management/service arrangements. Bank AUM, institutional portfolio valuations,103M holding subscribedcapital and400K Management subscribedcapital are not LP closes or paid reMYND checks. No unsupported stand-alone fund close is created. The authentic BNP Paribas Fortis group logo is the published brand used by its private-equity pages and own primary investment release; no independent PE-specific mark is implied.

Caroline Goddeeris is published by SFPIM with these professional/governance affiliations: Director — Board of Directors; Member — Remuneration Committee. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Catherine De Bolle is published by SFPIM with these professional/governance affiliations: Member — Audit Committee; Director — Board of Directors. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Damien De Vroey is published by SFPIM with these professional/governance affiliations: Director — Board of Directors. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Delphine Paul is published by SFPIM with these professional/governance affiliations: Governement commissioner — Board of Directors. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Diane Govaerts is published by SFPIM with these professional/governance affiliations: Director — Board of Directors; Member — Audit Committee. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Isabelle Callens is published by SFPIM with these professional/governance affiliations: Independent Administrator — Board of Directors; Member — Green Investment Committee; Member — Remuneration Committee. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Jeroen Overmeer is published by SFPIM with these professional/governance affiliations: Director — Board of Directors; Director — Board of Directors. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Koen Schoors is published by SFPIM with these professional/governance affiliations: Member — Green Investment Committee. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Koenraad Van Loon is published by SFPIM with these professional/governance affiliations: Chief Executive Officer — Executive Committee. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Nathalie Ombelets is published by SFPIM with these professional/governance affiliations: Member — Green Investment Committee. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Nicolas Pire is published by SFPIM with these professional/governance affiliations: Member — Green Investment Committee. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Olivier Henin is published by SFPIM with these professional/governance affiliations: Director — Board of Directors. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred. Olivier Henin is listed by Wallonie Entreprendre in its current public governance directory as board vice-chair. This is a governance affiliation with the regional public investment group rather than evidence of personal investment capital or a specific company board mandate.

Pierre Harkay is published by SFPIM with these professional/governance affiliations: Vice-president — Green Investment Committee. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Pieter De Cuyper is published by SFPIM with these professional/governance affiliations: Governement commissioner — Board of Directors. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Alexandra Vanhoudenhoven is published by SFPIM with these professional/governance affiliations: Head of Legal — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Axel Miller is published by SFPIM with these professional/governance affiliations: Chairman — Board of Directors; Chairman — Strategy Committee; Member — Audit Committee; Permanent guest — Remuneration Committee. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Dieter Berckvens is published by SFPIM with these professional/governance affiliations: Vice chairman — Board of Directors; Vice-chairman — Strategy Committee. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Hélène Volkova is published by SFPIM with these professional/governance affiliations: Legal advisor — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Jean-Albert Nyssens is published by SFPIM with these professional/governance affiliations: Vice chairman — Board of Directors; Vice-chairman — Strategy Committee; Member — Remuneration Committee. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred. Theodorus publishes Jean-Albert Nyssens with the following specifically scoped affiliation: Investment Committee member — Digital Expert (committee/LP representative affiliation, not an employment claim). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date.

Lauranne Zabeau is published by SFPIM with these professional/governance affiliations: Risk Manager — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Leen Van den Neste is published by SFPIM with these professional/governance affiliations: Independent Administrator — Board of Directors; Member — Green Investment Committee; Chairwoman — Audit Committee; Member — Remuneration Committee. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Martin Van der Wilt is published by SFPIM with these professional/governance affiliations: Office Manager — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Michiel Verheyden is published by SFPIM with these professional/governance affiliations: Investment analyst — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Luc van den Acker is published by SFPIM with these professional/governance affiliations: Accountant — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Luc Van den Broeck is published by SFPIM with these professional/governance affiliations: Business Controler — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Alan Vandenberghe is published by SFPIM with these professional/governance affiliations: Investment Manager — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Barbara Reypens is published by SFPIM with these professional/governance affiliations: Investment Manager — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Christophe Tits is published by SFPIM with these professional/governance affiliations: HR Business Partner — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Denis Ronday is published by SFPIM with these professional/governance affiliations: Investment Manager — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Elisa Spadaro is published by SFPIM with these professional/governance affiliations: Investment Manager — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Isabelle Philippe is published by SFPIM with these professional/governance affiliations: Investment Manager — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Josiane Uwase is published by SFPIM with these professional/governance affiliations: Legal Operations Officer — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Paul Schouls is published by SFPIM with these professional/governance affiliations: Investment Manager — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Sabine Perlot is published by SFPIM with these professional/governance affiliations: Accountant — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Alexandra Mineo is published by SFPIM with these professional/governance affiliations: Head of HR & Office Management — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Katrien Onderbeke is published by SFPIM with these professional/governance affiliations: Legal Operations Officer — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Victor Marinus is published by SFPIM with these professional/governance affiliations: IT Manager — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Virginie Meert is published by SFPIM with these professional/governance affiliations: Head of Control & Finance — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Adrien Gassée is published by SFPIM with these professional/governance affiliations: Financial Analyst — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Burim Demaj is published by SFPIM with these professional/governance affiliations: IT Officer — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Christophe Denis is published by SFPIM with these professional/governance affiliations: Investment Manager — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Christophe Madam is published by SFPIM with these professional/governance affiliations: Investment Manager — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Etienne Lauwereys is published by SFPIM with these professional/governance affiliations: Investment Manager — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

François Fontaine is published by SFPIM with these professional/governance affiliations: Investment Manager — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred. Neuvasq affiliation: François Fontaine has served as the General Advisor to the Société Fédérale de Participations et d’Investissements (SFPI) since December 2009. His responsibilities include overseeing investment projects in various sectors, such as new technologies, biomedical, real estate, waste treatment, and water and energy. Prior to his current role, François worked as an advisor for the tax unit of the Walloon Region where he was responsible for implementing and transferring regional taxes. He holds a Bachelor’s degree in law and tax sciences. François Fontaine is publicly named in the current Belgian official registry as a statutory permanent representative on the Newton Biocapital fund board. This is a specifically qualified fund-governance affiliation rather than an operating investment-team employee or a personal cash check. Newton Biocapital publicly documents this person as Statutory Permanent Representative — Fund I; Statutory Permanent Representative — Fund II. The affiliation is scoped to the published role, with no personal cash investment inferred. Bioxodes affiliation: François Fontaine holds a law degree from the University of Brussels and he is a specialist in Tax affairs. He was counsel in various public institutions and cabinet. He is currently general counsel to the Federal Holding and Investment Company (SFPI)-FPIM. SFPI is focusing its investments on innovative Belgian Companies, hoping to contribute to their financial and societal success story. Mr. Fontaine is also a Board member of several companies including biotechs.

Jérôme Lits is published by SFPIM with these professional/governance affiliations: Finance & Control officer — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Laetitia De Smet is published by SFPIM with these professional/governance affiliations: Legal Advisor — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Matthieu de Posch is published by SFPIM with these professional/governance affiliations: Investment Manager — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred. Theodorus publishes Matthieu de Posch with the following specifically scoped affiliation: Investment Committee member — SFPI (committee/LP representative affiliation, not an employment claim); LPAC member — SFPI (committee/LP representative affiliation, not an employment claim). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date.

Peter De Decker is published by SFPIM with these professional/governance affiliations: Investment Manager — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

William Goffaux is published by SFPIM with these professional/governance affiliations: Legal advisor — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Joël Decerf is published by SFPIM with these professional/governance affiliations: Communication — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Anouck Csordas is published by SFPIM with these professional/governance affiliations: Accountant — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Jodie Deffense is published by SFPIM with these professional/governance affiliations: Assistant — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Aïcha Azzaoui is published by SFPIM with these professional/governance affiliations: Accounting Manager — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Céline Vaessen is published by SFPIM with these professional/governance affiliations: Chief investment officer — Operating team; Chief Investment Officer — Executive Committee. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Jos Callens is published by SFPIM with these professional/governance affiliations: Investment Manager — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Koenraad Van Loo is published by SFPIM with these professional/governance affiliations: Chief Executive Officer — Operating team; Chief Executive Officer — Board of Directors; Managing director — Green Investment Committee; CEO — Strategy Committee. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Leon Cappaert is published by SFPIM with these professional/governance affiliations: Investment Manager — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Marc Ceurremans is published by SFPIM with these professional/governance affiliations: Investment Manager — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Michaël Vanloubbeeck is published by SFPIM with these professional/governance affiliations: Chief Finance Officer — Operating team; Chief Finance Officer — Executive Committee. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Sofie Cockx is published by SFPIM with these professional/governance affiliations: Assistant — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Tom Feys is published by SFPIM with these professional/governance affiliations: Chief investment officer — Operating team; Chief Investment Officer — Executive Committee. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

SFPIM, formerly styled SFPI-FPIM, is Belgium’s Federal Holding and Investment Company. The public-interest stock corporation is Société fédérale de Participations et d’Investissement / Federale Participatie- en Investeringsmaatschappij, enterprise BE0253.445.063, based in Brussels. Its coordinated bylaws record incorporation on September 16, 1994, followed by the 2006 merger; the governing law dates to 1962. SFPIM provides capital to Belgian companies across healthcare, biotechnology, strategic technology, aerospace, energy, mobility, finance and impact. Its investments on its own behalf are distinguished from state-delegated assignments and subsidiary portfolios. The current public directory lists 44 operating professionals, with CEO Koenraad Van Loo and board chair Axel Miller; committee and government-commissioner roles are separately qualified. External funds in which SFPIM invests are holdings, rather than funds necessarily raised or managed by SFPIM. State appropriations, statutory capital, assets under management and commitments are not paid investment proceeds or external fund closes. The 2020 annual report records a EUR 6 million reMYND subscription, 80% paid, implying EUR 4.8 million paid; the full subscription is not cash paid, and the financing is the same event announced in January 2021. SFPIM Real Estate reports its merger into the parent in June 2026. Other subsidiary and programme identities remain distinct.

Joyce CHENG is listed as Associate in Qiming Venture Partners’ current public team directory. The directory provides a named original portrait but no individual career biography.

Shaohua Liu is listed as Associate in Qiming Venture Partners’ current public team directory. The directory provides a named original portrait but no individual career biography.

Frost Lam is listed as Associate in Qiming Venture Partners’ current public team directory. The directory provides a named original portrait but no individual career biography.

Zhiyuan Zhou is listed as Vice President in Qiming Venture Partners’ current public team directory. The directory provides a named original portrait but no individual career biography.

Xiaofei Zhou is listed as Vice President in Qiming Venture Partners’ current public team directory. The directory provides a named original portrait but no individual career biography.

A TRPIM U.S. high-yield portfolio co-manager and credit research team leader. He serves on the adviser’s ESG committee; the July2026 High Yield Fund prospectus confirms his co-manager appointment effective June1,2026. His current official page uses a generic avatar, so no authentic portrait is claimed.

Leads TRPIM’s Small-Cap Stock Core Equity Strategy. The current Institutional Small-Cap Stock Fund prospectus identifies him as portfolio manager, with management responsibilities dating to2023 and its text describing sole-manager status since2024. His official biography also identifies group and trust-company vice-president affiliations.

A co-manager across TRPIM’s Capital Appreciation mutual fund and related ETFs, with responsibility for the strategy’s fixed-income research team. His official biography also identifies group and trust-company vice-president affiliations.

Xin Zhao is listed as Vice President in Qiming Venture Partners’ current public team directory. The directory provides a named original portrait but no individual career biography.

Cecilia Yin is listed as Vice President in Qiming Venture Partners’ current public team directory. The directory provides a named original portrait but no individual career biography.

TRPIM’s chief compliance officer, confirmed by its July1,2026 Form ADV, which dates the affiliation to October2024. A current authentic own portrait and additional independently established professional biography remain unavailable in this scoped research.

A director and treasurer of TRPIM, in addition to her parent-group chief-financial-officer responsibilities. Her career at T. Rowe Price began in2006 and includes corporate strategy and finance leadership, following roles at Constellation Energy, Energy Merchant and SG Cowen. She studied economics at William & Mary and holds a Virginia Darden MBA.

TRPIM’s chief legal officer and director, confirmed by the current adviser filing. His wider group general-counsel responsibilities cover legal, compliance and audit operations; he also leads governance liaison work for the registered funds. He holds degrees from Bucknell and Villanova law school.

Shidong Xi is listed as Vice President in Qiming Venture Partners’ current public team directory. The directory provides a named original portrait but no individual career biography.

Chairman and director of the distinct TRPIM legal adviser according to its July2026 Form ADV, alongside his parent-group chief-executive leadership. He joined T. Rowe Price in1997 as a financial-services analyst, later led a large-cap growth portfolio and took progressively broader investment leadership responsibilities. His background includes KPMG consulting, a Towson undergraduate degree and a Wharton MBA.

Directs ESG investing at TRPIM, including its integration into investment analysis, proxy voting and corporate engagement. He chairs the adviser’s ESG committee and holds a vice-president affiliation with the legal adviser.

Yuanhao Wang is listed as Vice President in Qiming Venture Partners’ current public team directory. The directory provides a named original portrait but no individual career biography.

Known professionally as Matt Mahon, he manages TRPIM’s U.S. Smaller Companies Equity Strategy and holds a group vice-president affiliation. The Peter/Matt identity is corroborated by a primary filed fund committee list; unrelated similarly named professionals are excluded.

Remus Wong is listed as Vice President in Qiming Venture Partners’ current public team directory. The directory provides a named original portrait but no individual career biography.

Leads trading at TRPIM and holds a vice-president role in that specific legal investment-adviser corporation.

Motao Sun is listed as Vice President in Qiming Venture Partners’ current public team directory. The directory provides a named original portrait but no individual career biography.

Became associate head of TRPIM on January22,2026, with responsibilities in investment steering, ESG governance and executive sponsorship of the group’s MOSAIC inclusion network. His announced appointment as head takes effect January1,2027 and is still future at the October8,2026 review. His education includes a Michigan MBA and a Pomona undergraduate degree.

Leads portfolio management for TRPIM’s small-cap value strategy and participates in its investment steering, ESG and group trading committees.

Researches healthcare-services companies for TRPIM. She supports investment advisory committees spanning the adviser’s allocation, small-cap and mid-cap funds, and holds a group vice-president affiliation.

Pu Shi is listed as Vice President in Qiming Venture Partners’ current public team directory. The directory provides a named original portrait but no individual career biography.

TRPIM’s chief investment officer and investment-strategy leader. He manages its Capital Appreciation investment products and jointly manages the related income-oriented fund and premium-income ETF. His official biography records multiple investment-industry awards and separate group/trust-company officer affiliations.

Bin Liu is listed as Vice President in Qiming Venture Partners’ current public team directory. The directory provides a named original portrait but no individual career biography.

Researches U.S. government policy and regulation as an associate analyst within TRPIM’s equity investment organization.

Jointly manages TRPIM’s U.S. mid-cap growth strategy and serves on its relevant fund advisory and investment steering committees. His official biography also identifies group and trust-company vice-president roles.

A TRPIM U.S. high-yield credit portfolio co-manager and investment steering committee member. The August2026 U.S. High Yield Fund prospectus confirms Douglas Zinser as co-manager fromJune1,2026 and announces Loome’s planned departure from that fund role onDecember31,2026. He remains a current co-manager at the October8,2026 review; the future transition is not treated as completed.

Lianbo Li is listed as Vice President in Qiming Venture Partners’ current public team directory. The directory provides a named original portrait but no individual career biography.

Dingzheng Li is listed as Vice President in Qiming Venture Partners’ current public team directory. The directory provides a named original portrait but no individual career biography.

A credit analyst researching U.S. high-yield issuers within TRPIM’s fixed-income business. His official biography confirms a separate group vice-president affiliation.

Responsible for quantitative company research at TRPIM and a member of the advisory committee for its Capital Appreciation and Income Fund. He also holds a group vice-president affiliation.

A portfolio specialist supporting TRPIM’s small-cap equity investment strategies. Her official biography also identifies a vice-president role at the parent group.

Tianqi Leng is listed as Vice President in Qiming Venture Partners’ current public team directory. The directory provides a named original portrait but no individual career biography.

A TRPIM investment analyst specializing in biotechnology companies and leading its healthcare research team. His group vice-president affiliation is distinct from any personal investment activity.

Shuo Huang is listed as Vice President in Qiming Venture Partners’ current public team directory. The directory provides a named original portrait but no individual career biography.

President and head of TRPIM, overseeing its investment organization and chairing the investment steering committee. His group-level responsibilities include executive leadership and support for business-resource and Baltimore entrepreneurship initiatives. The January22,2026 primary succession announcement schedules his retirement for the end of2026; he remains head at the October8,2026 review.

A current source-published co-manager of TRPIM’s U.S. mid-cap growth strategy. He participates in the associated mutual-fund advisory committees and the adviser’s investment steering committee. The current named official biography uses a generic avatar; an authentic portrait has not been established.

Weibin Hu is listed as Vice President in Qiming Venture Partners’ current public team directory. The directory provides a named original portrait but no individual career biography.

An investment manager on TRPIM’s Capital Appreciation team, working across its mutual fund and related equity and premium-income exchange-traded products. He also holds vice-president affiliations with the group and its trust company.

Yuxin Fu is listed as Vice President in Qiming Venture Partners’ current public team directory. The directory provides a named original portrait but no individual career biography.

Leads quantitative equity research at TRPIM and jointly manages its Capital Appreciation and Income Fund. His published responsibilities also include ESG oversight and model-risk governance across the affiliated advisers.

T. Rowe Price Investment Management, Inc. (TRPIM) is a separately SEC-registered Maryland investment adviser within the T. Rowe Price group, CRD314590 and adviser file801-121434. Its current July1,2026 Form ADV identifies T. Rowe Price Associates, Inc. as the direct controlling owner and T. Rowe Price Group, Inc. as indirect owner. Regulatory officers acquired their positions beginning May2021; the distinct investment business began operating March7,2022 after the publicly announced separation of six U.S. strategies. The founding field reflects the primary-confirmed March2022 operating establishment. Officers were already appointed in2021; an exact legal incorporation day is not independently established here, and those appointment dates are not represented as a separate founding event. Neither the group parent nor Associates is substituted for TRPIM when an issuer explicitly names accounts advised by this specific entity. The principal office is1307PointStreet,Baltimore,Maryland21231. It conducts independent investment research and decision making with shared group corporate functions, managing registered funds, institutional separate accounts and other client mandates across equities, allocation and high-yield credit. Its publicly named professionals include specialist biotech and healthcare analysts, quantitative researchers and investment managers. Actual deeptech/life-sciences exposure is established by Alamar Biosciences, a precision-proteomics platform company: its January2026 announcement names accounts advised by TRPIM as participants in completed USD56.5Mconvertible-note financing. That is client-account investment, not a treasury purchase by the adviser; the exact investing account, legal fund, individual ticket and lead status are unpublished. Conversion of these notes in an IPO would not be new cash. Primary own biographies and the July2026 adviser filing support a scoped25-person public investment/governance roster; this is not an invented full private employee directory or wholesale import of the parent group staff. Stephon Jackson remains president/head through2026; Steven Krichbaum became associate head January22,2026 and is announced to succeed him January1,2027. Parent executives RobertSharps,DavidOestreicher andJenniferDardis are included only for the distinct TRPIM legal director/officer roles explicitly confirmed by FormADV. The current filing lists no private funds in Schedule7.B.(1) or7.B.(2). Its public open-ended mutual funds, exchange-traded products and client accounts are not closed-end VC LP funds. Verified products are recorded with undisclosed fundraising amounts and closing dates; net assets, regulatoryAUM, GAV, fund fees, share purchases and strategy launch dates are not closed fresh capital. Current legal adviser/subadviser allocation is qualified separately for each fund, with broader product-wrapper audit retained as a documented gap. Own biographies currently use a generic avatar for BrianBerghuis and DouglasZinser, while compliance officer SavonneFerguson lacks a verified own current portrait; those three portrait gaps remain explicit. Every other included portrait is the genuine named official asset, not a generated image.

Xueyao Chen is listed as Vice President in Qiming Venture Partners’ current public team directory. The directory provides a named original portrait but no individual career biography.

Alexander Sinclair-Wilson is Principal at Qiming Venture Partners. Joined Qiming in 2024 and invests in healthcare. Earlier he supported biotherapeutic companies at SV Health Investors and Sanofi Ventures. He holds a stem-cell development doctorate associated with University College London and Yale, and natural sciences degrees from Cambridge.

Shuo Mao is Principal at Qiming Venture Partners. Joined Qiming in 2015 and invests in healthcare. Earlier he advised healthcare clients on product portfolios and market access at IQVIA. He studied biomedical engineering at Tsinghua and engineering and technology entrepreneurship at Rochester.

Cindy Liu is Principal at Qiming Venture Partners. Joined Qiming in 2018 and invests in biotechnology, including oncology, immunology, cardiovascular, CNS and respiratory diseases. Earlier she worked on strategy and transaction advisory at EY-Parthenon and healthcare consulting at IQVIA. She holds medical and preventive medicine qualifications from Fudan.

Jing Liu is Principal at Qiming Venture Partners. A healthcare investor at Qiming since 2020. Earlier he researched biotechnology at Deerfield and worked on early drug discovery at Novartis. He holds a doctorate in cell and developmental biology from Vanderbilt and a biological sciences degree from Tsinghua.

Qi Hu is Principal at Qiming Venture Partners. Joined Qiming in 2020 and invests in AI, infrastructure software and frontier technology. Earlier he worked at DiDi, Sinovation’s AI Institute and JD.com. His qualifications include AI studies at Edinburgh, an MBA at Peking University and computing and advertising degrees at Wuhan University.

Jinda Gao is Principal at Qiming Venture Partners. Focuses on healthcare investment. Earlier he invested in healthcare at Co-stone Capital and worked on listed-company and IPO audits at PwC. He studied at Zhejiang University.

Nan Chen is Principal at Qiming Venture Partners. Joined Qiming in 2015 and invests in technology. Earlier he spent ten years at Cisco China in engineering, consulting, product and business development. He holds engineering, business and finance degrees from Beihang, Peking University and Fordham.

Tom Schwarz serves on V-Bio’s strategic advisory board. His own biography describes more than20 years in biotechnology/medtech venture investing, co-founding Life Sciences Partners and Innovation Industries and earlier co-founding/CEO work at U-Gene Research. He has a pharmacy degree from Utrecht. This is the named investment adviser rather than an unrelated sportsperson or lawyer with the same name; no personal check is inferred.

Yi Zhang is Partner, China COO and General Counsel at Qiming Venture Partners. Leads legal, administrative and public affairs for Qiming in China. Earlier he held senior transaction and general counsel roles at Alibaba and Ant. He earned a law degree at Cornell and sociology degrees at Columbia and Renmin, with professional legal qualifications in China and the United States.

Willem Broekaert co-founded V-Bio Ventures in2015 and remains a managing partner. His own biography identifies earlier founding/CEO work at Fugeia and R&D leadership at CropDesign, after plant-biotechnology/pathology teaching at KU Leuven. His degrees include KU Leuven bioscience engineering master’s/doctorate and agricultural economics from IGIA/ESSEC. CurrentKBO names him director of the operatingBV and both legal managers; the legal funds remain distinct vehicles.

Oscar Zhang is Partner at Qiming Venture Partners. A healthcare investor at Qiming since 2015. Earlier he worked at WI Harper and China eCapital. His education spans biomedical engineering at Tsinghua, medical physics at Edinburgh and financial engineering at Imperial College London.

Janet Yu is Partner & Head of RMB Funds at Qiming Venture Partners. Joined Qiming in 2009 and leads RMB fundraising, operations and investor relations. Earlier she managed fund investing at the China Binhai New Area venture guiding fund. She holds chemistry, business and economics qualifications from Nankai University.

Shelley Margetson joined V-Bio as managing partner inDecember2020. Her own biography covers senior financial/business roles in European biotechnology, managing Merus’s May2016 NasdaqIPO as CFO and Gadeta’s build-to-buy deal with Kite/Gilead as CEO. She has a business-economics degree and CIMA membership. KBO separately registers her director roles at the operatingBV and Management2 fromNovember18,2020; that statutory date is distinct from the December joining-month statement.

Mathias Falcenberg joined V-Bio as venture partner inFebruary2025. His own biography describes Merck external-innovation work spanning protein degradation, AI-enabled drug discovery and biologics, prior Forbion venture experience and a biology background from TU Darmstadt. He earned a doctorate in Axel Ullrich’s Max Planck laboratory and co-founded an early drug-discovery company. AI-domain experience is scientific/investing expertise, not a personal investment or clinical approval claim.

Kuantai Yeh is Partner at Qiming Venture Partners. Invests in semiconductors, AI, enterprise software and consumer electronics. Earlier he worked at Highland Capital, Intel Capital China, Credit Suisse and Cypress Semiconductor. He holds Cornell engineering and business degrees and has semiconductor patents. His published portfolio includes Transwarp, Insta360 and TigerGraph.

Martin Solleveld is V-Bio’s finance manager and has supported the platform since its2015 inception. His own biography describes independent financial management since2004, earlier Arthur Andersen process-management/consulting and EY audit work, and experience with venture funds and biotechnology companies. He has business-administration and business-process/IT degrees. The public title does not prove a full-time employment contract or managing-partner role.

Katja Rosenkranz is a V-Bio Ventures partner who joined in2016. Her own biography describes prior analysis at Polytechnos, finance/business leadership at Advitos (formerly Hepa Wash) and investment/technology-transfer work at Ascenion. Her education includes a Witten/Herdecke biochemistry doctorate/master’s and an executive MBA in medical-device/healthcare management. The title follows the current own roster rather than outdated principal listings.

Bonnie Wang is Partner at Qiming Venture Partners. Joined Qiming in 2012 and invests in internet and consumer companies. Her portfolio includes NEIWAI, PETKIT and YESMRO. Earlier she worked in executive search at Egon Zehnder and journalism at Agence France-Presse. She studied journalism at Fudan and earned an MBA at CEIBS.

Christina Takke co-founded V-Bio Ventures in2015 and remains a managing partner. Her own biography reports more than15 years in European venture investing before the firm, including partnership at Forbion. She holds a Cologne developmental-biology doctorate and Darmstadt biology master’s. CurrentKBO records additionally identify her as director of the brand BV and both legal managers, and permanent representative of the managers on their respective fund boards. These corporate/fund roles do not imply a personal cash check.

V-Bio Ventures is a Ghent-based independent life-sciences venture-capital platform founded in2015 by Christina Takke and Willem Broekaert. It co-creates and finances early- and mid-stage companies developing therapeutics and differentiated biomedical technologies, with a preferred relationship to the separate Belgian research institute VIB. Its historical investment strategy also includes agricultural biotechnology. Current scientific investment expertise includes molecular biology, translational research, targeted protein degradation and AI-enabled drug discovery; its portfolio’s computational and neurological research links do not establish approved clinical benefit or that every investment is an AI company. The current website lists seven investment/finance professionals and adviser Tom Schwarz, with former adviser Johan Cardoen explicitly memorialised after his December17,2025 death. The Belgian operating/advisory company V-Bio Ventures BV is enterprise0758.544.057, formedNovember18,2020, distinct from the platform’s2015 origin and its registered managers V-Bio Management1 BV(0641.986.877) and V-Bio Management2 BV(0758.543.760). Actual fund vehicles V-Bio Fund1 NV(0642.766.540) and Fund2 NV(0759.685.291) are separately documented. Own primary releases confirm Fund1’s finalEUR76million close announcedDecember1,2016 and Fund2’s finalEUR110million close announcedMarch31,2022. The earlier63million and78million first closes belong to those same vehicles and are not additional funds or extra fundraising totals. The current website’s186million aggregate across two funds is managed-capital reporting, not a third fund close or company investment ticket. Explicit portfolio listings distinguish active and divested relationships, including neuroscience drug discovery and neurological-disease therapeutics; exits with maximum milestone values are not asserted as cash received. Actual issuer releases identify the institutional brand as a buyer, while an individual legal fund allocation is recorded only when published. VIB’s research functions, regulatory-grant programmes and a partner’s board service are not substituted for V-Bio’s separate corporate investment.

Shiyu Wang is Partner at Qiming Venture Partners. Focuses on internet and consumer investments, including Bilibili, Meitu and consumer technology businesses. He previously served as a managing partner at K2VC. He studied computer science and management information systems at Beihang University.

Six Robotics is an Oslo-based defence software company developing Valkyrie, an autonomy and coordination platform for unmanned systems. Its software connects vehicles from different manufacturers and enables operators to supervise coordinated mixed fleets through one software layer. Originating in research at the Norwegian Defence Research Establishment (FFI), the company works with the Norwegian Armed Forces and other NATO-aligned partners on interoperability, integration and operational testing. Six Robotics AS was founded in2023; the product is software for managing autonomous systems rather than a vehicle manufacturer.

Leads operations and organizational scaling at Six Robotics. Previously worked in strategy and business-model consulting at Kearney and Cardo Partners; studied finance at NHH.

Founded Six Robotics following work in the Norwegian Armed Forces special forces and advanced research projects at NORSOF and FFI. Studied computer science and economics at the University of Oslo.

Leads brand strategy and communications at Six Robotics. Previously a senior adviser and founding team member at Hekt, following work at First House.

Leads people strategy, internal operations and communications at Six Robotics. Previously VP Operations and Partner at Amby. Own company card says Head of People; biography and careers directory describe the wider communications remit.

Leads software development and platform architecture at Six Robotics. Previously built the software organization at Zivid and worked as Principal Engineering Manager at reMarkable; holds an MSc in mathematics from NTNU.

Leads product development at Six Robotics. Previously worked at Teledyne FLIR on the Black Hornet 4 and founded autonomous-drone company Staaker. Current team card says Chief Product Officer while its biography retains Head of Product.

Leads financial strategy and long-term planning at Six Robotics. Previously worked in consulting and investment banking and was a founding member and Principal at BearingPoint Capital.

Alain Nicod is Vi Partners’ founder & senior advisor. Founder and senior adviser whose entrepreneurial and investing career spans medical instrumentation, information technology and consumer businesses. He joined Vi Partners in2002 after more than a decade of founding, seed investing and executive work.

Daniel Gutenberg is Vi Partners’ venture partner. Venture partner who joined Vi Partners inJuly2003 with an IT focus. He founded Gutenberg Communication Systems in1991 and sold it to Telindus in2000, later becoming an angel investor. Personal investments remain distinct from institutional fund investments.

Elmar Schärli is Vi Partners’ finance manager. Finance manager and Swiss-certified public accountant with longstanding healthcare and technology accounting/audit experience. He founded Ante Treuhand in2003 and serves as its CEO; that external role is distinct from his Vi Partners affiliation.

Irene Seebacher is Vi Partners’ finance & operations manager. Finance and operations professional with experience across startups and larger companies in SaaS banking, Web3 and communications software. She studied at Copenhagen Business School and Sussex and has worked on strategy, corporate transformation and scalable financial processes.

Susan M. Gasser is Vi Partners’ advisor, healthcare and life sciences. Life-sciences adviser and chromatin biologist. She trained in biophysics at Chicago and biochemistry at Basel, led the Friedrich Miescher Institute from2004to2020 and became ISREC Foundation director in2021. She also has academic and life-science governance experience.

Bruno Trivelli is Vi Partners’ investment analyst. Investment analyst with robotics and technology-strategy training. He earned an EPFL robotics master’s and a management/entrepreneurship minor, and previously interned at Deloitte and founded a mobile technology business during his studies.

Cyrill Osterwalder is Vi Partners’ operating partner. Technology operating partner with security/privacy engineering experience at Google from2010to2018. Before Google, he led web-application security at Phion, later acquired by Barracuda Networks.

Maria Escala-Garcia is Vi Partners’ investment associate. Digital-health, medtech and biotechnology investment professional with a bioinformatics/oncology doctorate from the Netherlands Cancer Institute and Leiden. Before Vi Partners she advised healthcare organizations at IQVIA on precision-medicine and innovation topics.

Martina Gromo is Vi Partners’ investment associate. Investment professional with strategy, fintech and digital-innovation experience at Sygnum Bank and Bain. She studied international management at Bocconi and banking/finance at St Gallen.

Yassine Zaied is Vi Partners’ operating partner. Operating partner specializing in SaaS growth and market-category development. He previously held executive roles at Nexthink and helped build its digital-employee-experience business, bringing commercial scaling expertise to portfolio companies.

Arnd Kaltofen is Vi Partners’ managing partner. Healthcare investor and former physician with experience building companies and boards including Esbatech, Kuros, Activaero and Ganymed. He previously built healthcare venture-transactions work at KPMG and worked in medical-device/digital-health management. He holds medical, MBA and postgraduate computer-science qualifications.

Diego Braguglia is Vi Partners’ managing partner. Therapeutics and medical-device investor with operating experience in the pharmaceutical sector. His board work includes Endoart, Endosense, Amal and Sequana. He studied microbiology at Basel and earned a molecular/cellular biology doctorate at ISREC in Lausanne.

Gaetano Zanon is Vi Partners’ managing partner. Investor and entrepreneur with a background in London mergers/acquisitions and founding an environmental-assets investment business. He has advised European companies and institutional investors on strategic financing and divestitures and held leadership roles at Swiss financial institutions.

Julien Pache is Vi Partners’ partner. SaaS and deep-tech investor who previously led the investment team at Verve Ventures. He joined Bring! Labs as chief commercial officer in2019, then returned to Verve as a partner. He joined Vi Partners as partner inMarch2026.

Magdalena Plotczyk is Vi Partners’ principal. Healthcare investor with biomedical research training, including an Imperial College bioengineering doctorate and UCL nanotechnology/regenerative-medicine master’s. Her prior experience includes five years at healthcare-software growth investor MTIP.

Olivier Laplace is Vi Partners’ managing partner. Technology investor with entrepreneurial, software engineering and investment-banking experience. He built Swiss Post’s corporate venture activity and previously worked on corporate development and data analytics at Kudelski. He holds an IMD MBA alongside engineering training.

Grace Lee is Partner & Group COO at Qiming Venture Partners. Joined Qiming in 2009 and oversees group operations. Her background includes fund operations, fundraising and portfolio management. Earlier she worked at C. V. Starr Asia, PAI Partners and JAFCO Asia. She holds business and law degrees and CFA and accountancy qualifications.

Archean, operated by AIMATX Inc., develops new materials by combining AI design with laboratory synthesis and physical validation. It starts with the performance, manufacturing and cost constraints of an industrial application, designs a matching material and synthesis route, makes the material, and tests it under real operating conditions. Its technical origins are in UC Berkeley’s Bakar Institute of Digital Materials for the Planet. Earlier work under the AIMATX name focused on metal-organic and covalent-organic frameworks for applications such as carbon capture, water absorption and drug delivery. The company supplies validated materials and products rather than requiring customers to test lists of computational candidates themselves.

Luffy AI develops adaptive neural-network controllers for physical machines. Its neuroplastic AI combines evolutionary algorithms and neural networks trained in simulation, then adapts on the device to changing loads and operating conditions. The controllers run within existing embedded hardware and can replace or complement conventional control loops without repeated calibration or cloud retraining. Applications include motors and industrial drives, robotic positioning, thermal and furnace control, drones and automotive powertrains. Based at Culham Campus in Oxfordshire, the company works with industrial partners to turn control prototypes and pilots into deployable products.

Joined BGF in 2024, focusing on deep technology and climate. Previously an investment director at Longwall and spent sixteen years at the Science and Technology Facilities Council.

David Chu is Partner at Qiming Venture Partners. Leads fundraising and investor relations for Qiming’s USD funds. Earlier he oversaw private-equity and venture commitments, co-investments and secondaries at LACERA and co-founded SVP Capital Advisors. He earned an MBA at Cornell and studied business administration at Berkeley.

Kan Chen is Partner at Qiming Venture Partners. A scientist and healthcare investor who joined Qiming in 2016 and co-leads its healthcare practice. Earlier he worked at Cleveland Clinic, Harvard Medical School, Johnson & Johnson and Hengrui. His investment work includes drug development and biotechnology, with board experience at Insilico Medicine, LaNova and MediLink.

Gary Rieschel is Founding Managing Partner at Qiming Venture Partners. Co-founded Qiming in Shanghai in 2006. Earlier he held executive positions at Intel, Sequent, Cisco and Softbank, establishing Softbank’s US venture group in 1995. His career spans technology company operations and venture investing in the United States and China.

Alex Zhou is Managing Partner at Qiming Venture Partners. Invests in AI, robotics and emerging technology. Before Qiming he worked at Kleiner Perkins and led HP’s China storage business. He studied computer science at Harbin Institute of Technology and earned an MBA at Columbia. His published portfolio includes Zhipu AI, Biren, UBTech and StepFun.

Duane Kuang is Founding Managing Partner at Qiming Venture Partners. Co-founded Qiming in 2006 after leading Intel Capital’s China investments and holding management roles at Cisco. His investing covers AI, automation and information technology, including robotics and autonomous driving. He studied computer science at Stanford and San Francisco State and earned an MBA at Berkeley.

Qiming Venture Partners is a China-focused venture investment platform founded in 2006, investing at early and growth stages in technology and healthcare. Its current published team includes 40 named investment and operating professionals, led by founding managing partners Duane Kuang and Gary Rieschel and managing partners William Hu and Alex Zhou. Investments span AI models and infrastructure, semiconductors, robotics, autonomous systems, biotechnology, diagnostics, medical devices and healthcare services. Relevant portfolio companies include Alamar Biosciences, Insilico Medicine, TandemAI, SceneRay and GenLight. Current contacts list offices in Shanghai, Beijing, Hong Kong, Suzhou and Singapore. The February2024 website terms identify Qiming Weichuang Venture Capital Management (Shanghai) Co., Ltd. and affiliates as Qiming; the copyright footer names the Beijing affiliate. USD fund GP and legal vehicle identities are separately documented in issuer filings. This profile represents the China platform, preserving the distinct existing Qiming Venture Partners USA profile and its financial references. The USD Fund VIII announcement reported USD2.5 billion collectively for the main and parallel healthcare funds, not USD2.5 billion for each. RMB Fund VII first closed at RMB4.7 billion in July2022 and finally at RMB6.5 billion in May2023; the first close is included in the final total. USD Fund VII first closed at USD1.1 billion in April2020 and finally at USD1.2 billion in November2020. Historical partner Nisa Leung departed in February2025 and is not included in the current roster. Firm-level aggregate capital, investment targets and proposed Fund IX offerings are not recorded as separate cash raises. The March31,2026 SEC exempt-reporting filings identify Qiming Cayman, Ltd. (CRD160844) as the Qiming Venture Partners adviser for older USD fund vehicles and Qiming Global Management, LLC (CRD309395) as adviser for USD VII, VIII, VIII-HC and IX-A/B/C vehicles. Both list Hong Kong principal offices. They are related China-platform legal advisers, with separate vehicles and GPs; no SEC registered-adviser status is claimed. Form ADV asset values are portfolio gross assets rather than capital newly raised. Current Fund IX legal vehicles are documented without a verified final-close amount.

ORBES is a California space robotics company developing autonomous machines for inspection, maintenance and filming around orbital infrastructure. Its ORB robot is designed to work inside space stations, supporting routine checks, item logistics and camera operations. Exo-ORB is an escort spacecraft intended to inspect stations and satellites from outside, providing imagery and identifying infrastructure problems. The company also builds zero-gravity test rigs to train and validate its robots on Earth. Its legal company is Orbital Entertainment Supply Inc., a Delaware corporation operating in California. The systems remain in development; planned demonstration missions are future deployments.

Waffle Video develops software and a contributor network for collecting real-world video datasets for robotics and physical AI. Its capture app records video to a defined project specification with motion, depth and spatial sensor data, checks delivered clips, and transfers data into customer storage. The platform manages collection projects and contributors, with MCAP delivery when required. GRID connects buyers seeking video data with vetted capture partners offering recording capacity. Waffle Video, Inc. is based in Los Angeles and has produced datasets since 2024.

Camera and filmmaking adviser at ORBES; previously worked with Canon and Band Pro and selected cameras for an ISS IMAX documentary. Distinct from the BEE Partners investor of the same name.

Christine Mathews is Versant Ventures’ current Advisor. Current advisor, previously consulting HR head2006–2020. Runs startup-focused HR consulting and holds Stanford human-biology education.

Robin Praeger is Versant Ventures’ current Advisor. Current advisor, formerly Versant CFO2000–2022 and managing director from2005. Earlier Arthur Andersen tax partner; Berkeley degree and Golden Gate tax masters.

Kenan Sagouspe is Versant Ventures’ current Portfolio Analyst. Portfolio analyst supporting capital allocation and fund analytics after TD Cowen healthcare investment banking, Pontifax and UCSF work; UCLA economics graduate.

Kim Macniak is Versant Ventures’ current Controller. Oversees fund accounting, valuations and GP reporting. Former PwC assurance director, UC Santa Barbara graduate and California CPA.

Steve Edelson is Versant Ventures’ current VP, IR & Communications. Leads investor/external communications after BioCentury editorial and financial-industry coverage; Northwestern biotechnology and biochemistry education.

Lara Hoth is Versant Ventures’ current VP, Management Company Finance and Accounting. Finance/accounting leader since2016, previously Novartis controller and PwC assurance/consulting professional; UC Berkeley graduate.

Cathy Dring is Versant Ventures’ current Legal Counsel. Legal counsel sinceDecember2012, with previous Pillsbury and Cooley venture-law practice. USC law degree and UC San Diego biophysics education.

Rich Van Doren is Versant Ventures’ current Chief Financial Officer. Former Samsara CFO with earlier Pacific Grove, Marcato and Cannell finance/operations roles. San Francisco finance graduate with Golden Gate tax training.

Ed Olhava is Versant Ventures’ current Scientist-in-Residence. Medicinal chemist with former IFM preclinical leadership and Epizyme/Millennium discovery roles, including co-invention of ixazomib. Stanford chemistry graduate with Harvard doctorate.

Max Eisenberg is Versant Ventures’ current Chief Operating Officer and General Counsel. Legal and operational leader, previously Polaris general counsel/compliance officer. Northwestern-trained lawyer with Duke history degree.

Vincent Ruland is Versant Ventures’ current Entrepreneur-in-Residence. Former Bayer R&D strategy and operations leader, trained in neuropathology. Holds Münster MD and Cambridge bioscience-enterprise MPhil.

Rick Dewey is Versant Ventures’ current Entrepreneur-in-Residence. Physician-scientist with human-genetics discovery experience, Stanford medical/internal-medicine/cardiology training and Harvard chemistry/physics education.

Maud Lazare is a Partner at Seroba responsible for Investor Relations, joining in 2023. Her prior experience includes Truffle Capital, Massena Partners, its private-markets spin-off Essling Capital, La Française and Richelieu Finance. She holds master’s degrees in fundamental mathematics from ParisVI and in modelling, optimization, decision and organization from ParisDauphine.

Giorgio Ottaviani is Versant Ventures’ current Operating Partner. Ridgeline operating leader since2018, previously Roche drug-metabolism/safety executive and Novartis/Merck-Serono researcher. Geneva pharmaceutical-chemistry PhD and certified toxicologist.

Andrew Duignan is a Partner and Chief Financial Officer at Seroba, joining in 2011. He previously worked as a financial controller, tax consultant at RSM Farrell Grant Sparks and in positions at AIB Bank of New York and Citco Fund Services. He studied accounting and finance at Dublin City University and qualified as a chartered accountant, tax consultant and financial adviser.

Andrew Jefferson is Versant Ventures’ current Operating Partner. Joined2018 after Roche molecular-solutions business-development leadership, earlier Roche Pharma and Ciba-Geigy/Novartis work. Nottingham chemistry graduate with Brighton MBA.

Jennifer McMahon is a Partner at Seroba. She joined the investment team in 2011 and became a Partner in 2022, investing in medical devices and therapeutics. Her education combines pharmacology at University College Dublin, biotechnology and business, and a diploma in company direction. She has served in healthcare-businesswomen and private-equity diversity initiatives and teaches venture investing as a guest lecturer.

Laura Quock is Versant Ventures’ current CBO-in-Residence. Supports portfolio business development after Gilead corporate-development work and earlier Genentech, AbbVie and Abbott experience. Berkeley MBA/chemical-engineering graduate and Purdue chemical-engineering undergraduate.

Bruno Montanari is a Partner at Seroba, joining in 2017. His prior roles include life-sciences partner at Omnes Capital, venture positions at Atlas Venture and CDP Capital, and healthcare investment banking at Deutsche Bank and Merrill Lynch. He holds a pharmacy doctorate from Université René Descartes and a strategic-management master’s degree from HEC. The current manager directory lists Sibylla Biotech as an observer affiliation; appointment terminology is kept distinct from historical issuer board announcements.

Michael Wong is Versant Ventures’ current Principal. Previously worked in Flagship company creation and founded ARCHITECHealth and Industry Link. Holds McMaster medical-sciences doctorate and Western physiology/pharmacology degrees.

Nikita Sharma is Versant Ventures’ current Principal. Former Novartis mergers-and-acquisitions director and Sandoz analyst, with earlier Axalta business development and Symbiosis MBA.

Alan O’Connell is a Partner at Seroba, joining in 2003. His career includes pharmaceutical product and business development at Elan and American Biogenetic Sciences, pharmacovigilance at the UK medicines regulator and venture experience at Estée Lauder Investments. He conducted postdoctoral neuroscience research at University College Dublin and holds a Galway neuropharmacology PhD and a University of London pharmacology master’s degree. The manager publishes his Alzheimer’s Drug Discovery Foundation scientific advisory affiliation.

Ariel Kantor is Versant Ventures’ current Principal. Biotechnology investor with earlier company-building experience; Duke bioengineering/finance education and Oxford clinical-neuroscience doctorate as a Rhodes Scholar.

Daniel O’Mahony is a Partner at Seroba, joining in 2009 after corporate-venture work at Elan and advisory/partner experience at Kernel Capital. His expertise spans pharmaceutical development, licensing, intellectual property and commercialization. He has held academic research positions in Ireland and the UnitedStates and established the University of Galway technology-transfer office. He holds a Cork PhD and a technology-management business degree from University College Dublin. His source-published outside board affiliations are corporate governance, not personal financing checks.

Adam Knight, PhD is a cofounder and partner of Neuro.VC, focusing on therapeutics for neurodegenerative diseases. Primary MJFF and UniversityofAlabama biographies describe his previous founder/CEO/CBO roles at Neuron23 and work translating genetically defined neuroscience into drug development. He studied biological sciences at Alabama and completed a doctorate at Cambridge; earlier professional experience includes KleinerPerkins, IQVIA and MiltenyiBiotec. Earlier Neuron23 fundraising is not a Neuro.VC fund close.

Ciara Green is Operations Manager at Seroba, joining in 2024 after professional-services and B2B commerce roles. She previously managed the office at Merkle Ireland and worked in marketing. Her education includes contemporary culture and society at Dublin City University, project-management certification and a higher diploma in English from Maynooth.

Dermot Fuller is Financial Controller at Seroba and joined in July 2026. His prior roles include Finance Director of JCPS Mechanical, COO of Elkstone and CFO of Brown Brothers Harriman’s Irish entities. He began his career at Goodbody Stockbrokers. He holds a business studies degree from Dublin Business School, is an FCCA and completed quantity surveying training at ATU Sligo.

Elana Lockshin is currently an analyst at Jeito. Jeito’s own biography confirms prior healthcare investment experience with the SanFrancisco-based Neuro.VC fund and a doctorate in neurobiology fromDuke. Her Neuro.VC affiliation is historical and its exact jobtitle/tenure is not published in that primary biography. The authentic portrait is from her current ownJeito2026 directory, not asserted as a NeuroVC-era photograph. Elana Lockshin is Jeito Capital’s current Analyst. Earlier healthcare investing at Neuro.VC and neuroscience academic research; Duke neurobiology PhD, Boston University neuroscience BA and NIH F31 fellowship.

Joel Drewry is Versant Ventures’ current Principal. Biotechnology principal with scientific training and research experience recorded in his current own manager biography. Joined2014 and helps create biotechnology companies in North America. Holds a2012 University of Toronto organic-chemistry doctorate.

Mehmet Badur is Versant Ventures’ current Principal. Scientist and principal supporting biotechnology investments and company creation; education and external roles remain scoped to his current published biography. JoinedMarch2022 and promoted principalOctober2022 after Rheos discovery, business-development and strategy work. Holds UC San Diego bioengineering doctorate.

Omer Siddiqui’s public self-authored professional profile identifies an affiliation with Neuro.VC in the SanFranciscoBayArea without an operating title. His professional background is clinical drug development and business operations. VanquaBio’s own December12,2023 appointment announcement identifies prior ChiefDevelopmentOfficer work and earlier clinical-development operations at Alector/Harpoon. The reviewed formerVanqua biography URL now404s; no currentNeuroVC partner title or missingportrait is invented.

Sophie Hughes is an Investment Analyst at Seroba. Before joining in 2023, she conducted pharmaceutical research at GlaxoSmithKline and Cancer Research UK Therapeutic Discovery Laboratories. Her Oxford oncology DPhil examined pancreatic cancer and the immune microenvironment; she also developed biotech market-entry strategies through the Creative Destruction Lab. She holds a Bristol degree in cancer biology and immunology.

Zach Sweeney is Versant Ventures’ current Venture Partner. Discovery scientist and biotechnology executive whose own biography describes medicinal-chemistry and therapeutic development experience. Former Interline co-founder/CEO and Denali CSO, with additional Genentech, Roche, Novartis and Revolution discovery leadership. Chemistry education includes Stanford undergraduate, Berkeley doctorate and Harvard postdoctoral research.

Neuro.VC is a neurodegeneration-focused venture investment firm publicly corroborated by portfolio-company financing disclosures and founder biographies. It invests in therapeutic approaches for Alzheimer’s disease, Parkinson’s disease and ALS. The University of Alabama and the Michael J. Fox Foundation identify Adam Knight, PhD as cofounder and partner; he previously founded and led Neuron23, working in precision neurology and genetically defined disease. Its commissioned brand designer Cardigan identifies John Doerr as a cofounder, independently distinguishing the institution from similarly named NeuroVentures or NeuronVC businesses. Capsida’s own May2025 corporate deck explicitly names NEURO.VC against a12MUSD convertible note in2023, establishing actual institutional financing rather than a guessed personal founder check. A2025 peer-reviewed conflict-of-interest statement names Vanqua Bio, Neuron23 and Capsida as institutional investments; exact rounds for the first two are not inferred. A current public self-profile discloses Omer Siddiqui’s Neuro.VC affiliation without an operating title, and Jeito’s current biography identifies Elana Lockshin’s prior investment experience with Neuro.VC. No complete current staff directory, exact legal LLC/LP entity, regulatory manager registration, verified operational website or fund-close size was identified in the reviewed primary sources. The matching neuro.vc address currently redirects to a parked landing page and is not asserted as the operational website. These coverage gaps remain explicit.

Seroba is a European life-sciences venture capital firm investing in biotechnology, therapeutics and medical technology. Headquartered in Dublin with offices in Paris and Milan, its public investment team combines pharmaceutical research, neuropharmacology, drug discovery, corporate development and financial experience. Relevant portfolio areas include stroke intervention, migraine neuromodulation, computational protein-folding drug discovery and digital healthcare. The current legal notice identifies Seroba Health Capital Management Limited, Irish company579226, trading as Seroba and authorised as a EuVECA manager and registered AIFM. Historical Seroba Life Sciences and Seroba Kernel fund names are source-qualified; Kernel Capital itself is not merged into this manager. The firm announced a EUR123million final close of FundIV on February1,2024 and a EUR100million first close of FundIII on February2,2017. Those are fund capital announcements, distinct from company investment allocations. Its current website publishes ten named partners, venture, investment, finance and operations staff, including Financial Controller Dermot Fuller, who joined in July2026. Seroba participated in Sibylla Biotech’s actual EUR23million SeriesA announced October4,2022; the company’s financing owner records that relationship separately, with individual allocation undisclosed.

Alicia Levey is Versant Ventures’ current Venture Partner. Biotechnology operating leader and venture partner whose own career biography describes company building and discovery leadership. Previously Pionyr president/COO, Tempest CBO and Inception business-development executive, following Boston Consulting Group work. Holds Stanford cancer-biology doctorate.

Monal Mehta is Versant Ventures’ current Venture Partner. Venture partner with source-published biotechnology research and operating experience; current manager affiliation is distinct from personal investment attribution. Former Avidity private-fund managing director with earlier Pfizer business development and Navigant consulting. Holds a cancer-biology doctorate from the University of Medicine and Dentistry of New Jersey.

Tom Hudson is Versant Ventures’ current Venture Partner. Physician-scientist and venture partner with extensive genomics and pharmaceutical research leadership, as described in his current primary biography. Previously AbbVie chief scientific officer and founding scientific president of the Ontario Institute for Cancer Research. Holds Montreal medical degree and McGill/MIT postdoctoral training.

Kevin Grove is Versant Ventures’ current Venture Partner. Cardiometabolic researcher who established Novo Nordisk obesity research in Seattle after Oregon Health and Science University academic work.

Peter Emtage is Versant Ventures’ current Venture Partner. Drug-development executive with prior cell-therapy and immunology leadership; Guelph molecular-biology education and McMaster doctorate, followed by National Cancer Institute research.

Richard Glynne is Versant Ventures’ current Venture Partner. Immunology/genetics scientist with previous Novartis discovery and business-development roles, ICRF doctorate and Stanford postdoctoral research.

Nigel Sheail is Versant Ventures’ current Partner. Healthcare dealmaker with prior Novartis M&A/business-development leadership and earlier Bayer and Roche senior transaction roles.

Markus Enzelberger is Versant Ventures’ current Partner. Protein-engineering expert and former MorphoSys CSO. Supports Basel company formation through Ridgeline; holds Stuttgart doctorate.

Tom Woiwode is Versant Ventures’ current Managing Director. Biotechnology investor and company builder with earlier XenoPort medicinal chemistry experience and Stanford chemistry doctorate; formal legal first name Thomas is source-qualified.

Andrea Fetrow’s own public professional profile identifies Morningside Technology Advisory LLC and an executive-assistant background in biotechnology. Morningside’s digital-health team members publicly acknowledge her team and summit work. Exact current managerial seniority is undisclosed and is not inferred from third-party staff directories.

Andrew O’Connor previously invested at Morningside in climate technology, energy, generative AI and advanced manufacturing. Bronze Valley’s current biography confirms he joined it as a principal in June 2026, so his Morningside affiliation is historical. He holds degrees from Auburn, Harvard engineering and Harvard Business School; the exact departure day is undisclosed.

Carlo Rizzuto is Versant Ventures’ current Managing Director. Helped establish the New York investing operation after Basel service. Previously led Novartis development teams and advised pharmaceutical clients at McKinsey; Harvard virology PhD.

Dan Shpilsky publicly identifies his current Morningside affiliation and describes his work with its digital-health investment team and portfolio companies, including SimpliFed. Published professional activity confirms his investor role; no unsupported partner title or exact employment date is inferred.

Elijah Chang is identified by Origin Medical’s own advisory directory as an investment professional at Morningside Technology Advisory LLC. His own current professional profile describes Morningside’s digital-health team and portfolio-acceleration activity. His Duke Fuqua education is publicly identified.

Joseph Brower is named as a member of Morningside’s digital-health team in Elijah Chang’s own 2025 summit publication. His current public profile identifies Mercor Intelligence and a Harvard neuroscience degree. The Morningside role is therefore source-qualified historical, with exact departure date and title undisclosed; unrelated Joseph Brower profiles are excluded.

Peter Hu is identified in his September 2026 Sbur Decision Lab interview as an investor on Morningside Ventures’ digital-health team. His discussion addresses AI-enabled healthcare, early-stage investment and patient capital. His published affiliation is distinguished from unrelated same-named professionals.

Chi-Wai Lee’s own public professional profile identifies Morningside Technology Advisory LLC and a venture-investment focus on innovative software technology. He is also named on Morningside’s official company profile. His specific partner seniority and exact appointment date are not publicly verified.

Jerel Davis is Versant Ventures’ current Managing Director. Joined2011 and helped establish Canadian venture creation. Prior McKinsey adviser and Amgen scientist, with Stanford doctoral and postdoctoral training.

Mick Sawka is identified by Cairn Surgical’s current board directory as an investment advisor at Morningside Ventures. Issuer financing announcements from Catalant and Semios also identify his Morningside investment work. His company-board affiliation is distinguished from his manager advisory role.

Ruoxi (Rosy) Hu, PhD, publicly identifies herself as a current member of Morningside Technology Advisory LLC’s biotechnology investment team. Apnimed’s own appointment announcement identifies her molecular-biology doctorate from Harvard and prior Mass General Brigham Ventures and Clarion work. Her current professional affiliation is supported by her own public profile.

Stephen Bruso joined Morningside Ventures in 2019 and focuses on early-stage digital-health businesses. Freespira identifies his digital-health investment and board work, including Cognito Therapeutics, Curai Health and Neuroelectrics. The current primary biography supports an investment-professional affiliation without inferring an undisclosed general-partner appointment.

Wes Nolin publicly identifies himself as a member of the Morningside investment team since 2007. His current public professional profile names Morningside Technology Advisory LLC; Vigeo’s original January 2020 fact sheet identifies Westley Nolin as a Morningside Ventures director. Exact appointment dates are undisclosed.

Anthony Aiudi is identified by Neutrolis as both its current chief executive officer and a Morningside investor. His professional background spans biotechnology investment and company development. This Morningside role is recorded as concurrent with his published operating appointment; cumulative personal investment activity is not a firm fund close.

Isaac Cheng, MD, is the physician on Morningside’s investment team, which he joined in 2006. His work covers biopharmaceutical and healthcare investments. MedRhythms identifies his Tufts MD and prior work at Serica Technologies and Novartis. He is distinct from the same-named Bain Capital Life Sciences professional.

Finvolve is an Indian platform connecting wealth managers and accredited investors with startup investment opportunities across early, growth and pre-IPO stages. Its public investment themes include robotics, unmanned systems and space, artificial intelligence, energy and mobility, circular-economy technologies and healthcare. Founded as a joint initiative of India Accelerator and Finolutions, the brand presents a network of funds with separate regulated managers. Its current operator, Finvolve Ventures LLP, provides technology and IT services to those managers and expressly does not act as an investment manager, adviser or distributor.

Revenant VC is a venture-secondaries investment firm based in San Francisco and Boston. It provides liquidity to founders, early investors, employees and limited partners through selective investments in venture-backed companies. Its approach combines relationships with company stakeholders and venture investors with company-level underwriting. Its team brings experience in venture investing, fund allocation and building technology companies.

Co-founded Revenant after investing at Fifth Down Capital and co-leading Accomplice’s West Coast office. Her earlier operating experience includes strategy and corporate development at PayPal and Venmo.

Invests at Revenant after experience with venture funds, an endowment and a family office. He began his career at Glasswing Ventures and completed an MBA at Harvard Business School.

Works with Revenant after founding gaming communications company Vivox, which was acquired by Unity. His prior experience includes Jazzya Investments, investment banking at Goldman Sachs and legal work at Sullivan & Cromwell.

Co-founded Revenant after co-founding Accomplice. His prior investing career includes SoftBank, Grandbanks Capital and Atlas, with extensive experience serving on technology-company boards.

Lauren Popov is an associate at Westlake BioPartners. She supports investment evaluation after leading translational biology at Novome Biotechnologies, including microbial medicines advancing from preclinical research through Phase 2 studies. She trained at Stanford University and UC Berkeley.

Brogan Perrelli is vice president of finance and operations at Westlake BioPartners. She directs accounting, financial operations and strategic operating initiatives. Earlier experience includes KPMG, Crowe Horwath and the private-equity finance team at ICONIQ Capital.

Desmond Padhi is an operating partner at Westlake BioPartners. He helps conceive and advance drug-development programs across portfolio companies. He previously served as Capsida’s founding chief executive officer and Latigo’s interim chief executive officer, following two decades at Amgen in translational medicine. These company CEO assignments are historical.

Kelli McKeirnan is director of administration at Westlake BioPartners. She supports the firm and its incubated businesses after more than two decades as an executive administrator at Amgen. She studied sociology and business at California State University, Dominguez Hills.

Armando Alvarez is finance manager at Westlake BioPartners. He handles accounting, finance and operations after accounting roles at PwC and The Walt Disney Company. He is a certified public accountant with accounting degrees from the University of Denver.

Jennifer (Jenn) Kercher is general counsel at Westlake BioPartners. She previously served as chief legal officer and chief operating officer at Section 32 and as general counsel at GV. Earlier positions included Google M&A legal work and practice at Wilson Sonsini Goodrich & Rosati.

Mira Chaurushiya is a managing director at Westlake BioPartners. She previously partnered at 5AM Ventures and supported drug-development and life-sciences technology companies. She earned a doctorate in biological sciences through UC San Diego and the Salk Institute and completed postdoctoral research at Genentech.

David Allison is a managing director at Westlake BioPartners. He joined the leadership team in 2023 after partnering at 5AM Ventures and earlier investing at Versant Ventures, Split Rock Partners and PTV Healthcare Capital. His work combines company formation, healthcare investing and translational research.

Jina Elise Swartz is a filed Parkinson’s Research Ventures Limited director fromMay30,2023. FreeOxBiotech’s current ownnamedbiography identifies her as ChiefMedicalOfficer and publishes her genuineportrait. She is a physician and neuroscientist with pharmaceutical/clinicalresearch experience. The separate statutorycharityinvestmentunit affiliation does not imply a personal financing ticket.

Dr Burrinder Grewal is a filed Parkinson’s Research Ventures Limited director fromMay30,2023. PLFPharma’s own advisorybiography identifies him as managingdirector of NHSHuddersfieldPharmacySpecials, with previous life-science venture/businessbuilding experience including IPGroup and DeloitteConsulting. He holds pharmacy/economics degrees and a doctorate in transdermaldrugdelivery/formulation. Institutional directorship and external advisoryroles do not establish personal equity checks.

Fiona Elspeth Ducotterd PhD is a statutorydirector of Parkinson’s Research Ventures Limited fromFebruary20,2026. UCL’s ownSeptember17,2026 biography identifies the same neuroscientist as ChiefScientificOfficer of its Alzheimer’sResearchUK DrugDiscoveryInstitute, leading a26-scientist researchportfolio. Her prior industry work included neurology and genetically defined diseases at Eisai,GSK,Vertex andMSD, across theUK,US,Japan andChina. Academic/drug-development credentials do not prove individual investment tickets or clinical efficacy.

Jonathan Robert Behr PhD is a filed director of Parkinson’s Research Ventures Limited fromMay30,2023. SVHealthInvestors’ own2019appointment and2024publication establish the same scientist/venture investor’s DementiaDiscoveryFund partner identity, MITbiologicalengineeringPhD, earlier JDRFT1DFund leadership and life-science commercialization experience. These dated external biographies do not invent current responsibilities or a personal cash check.

Lilian Alcaraz is a statutory director of Parkinson’s Research Ventures Limited, appointedFebruary20,2026 in CompaniesHouse. A dated JohnsonAndJohnson own innovation2022directory identifies the same named neuroscience earlypartnering professional; that historical employer publication is not treated as a current2026 job. More extensive current biography and an authentic own named portrait were not verified.

Chris Swain is a published External Drug Discovery Adviser with the Parkinson’s Research Ventures programme. Own biography: Chris founded Cambridge MedChem Consulting in May 2006, where he remains Director. Prior to that he spent 20 years at Merck where he was a Senior Director responsible for a medicinal chemistry and the computational chemistry research group, He was the Chemistry Director of the project team that discovered and developed the NK1 antagonist Emend. His current activities include, providing medicinal chemistry and computational chemistry support to small and mid-cap sized Pharma companies, academic groups and start-ups. Several of these projects have resulted in molecules undergoing clinical studies. Chris has over 100 peer reviewed publications. The adviser/operating affiliation is distinct from a statutory directorship or personal cash check.

Ann Hayes is a published External Drug Discovery Adviser with the Parkinson’s Research Ventures programme. Own biography: Following her PhD, Ann spent 22 years at GSK and was appointed Therapeutic Director for CNS diseases in Drug Discovery in 1995. In 2001, Ann set up as an independent consultant, and has since co-founded 3 companies and sat on the board of several others.  She consults for small companies in CNS diseases and Drug Discovery, alongside advising charitable organisations including Alzheimer's Research UK. The adviser/operating affiliation is distinct from a statutory directorship or personal cash check.

Manfred Auer is a published External Drug Discovery Adviser with the Parkinson’s Research Ventures programme. Own biography: Following his PhD at the MPI for Medical Research in Heidelberg, Manfred spent 20 years at Novartis in which he progressed from Labhead to worldwide Executive Director for Innovative Screening Technologies in 2004. In 2009 he made was Professor for Chemical and Translational Biology at the University of Edinburgh, UK, where he stayed for 15 years. Manfred’s expertise lies in the development and application of drug discovery technologies with focus on computational and experimental quantitative biology. Manfred’s current work roles include memberships of boards of Directors and Advisory Panels, and consulting for biotech companies, charitable organisations and universities. The adviser/operating affiliation is distinct from a statutory directorship or personal cash check.

Michael Rowley is a published External Drug Discovery Adviser with the Parkinson’s Research Ventures programme. Own biography: Mike has 35 years of drug discovery experience and has held senior medicinal chemistry leadership positions at Merck Sharp and Dohme (MSD) in the UK, Italy and Switzerland, and at AstraZeneca in Sweden. He led teams which discovered 3 marketed drugs (Isentress, Zapatier, Zejula), has been a member of governance bodies in large pharma, and has multiple experiences with CNS drug discovery projects. For the past 5 years he has consulted with biotech companies, universities and VC funds. He is a Fellow of the Royal Society of Chemistry, a Hero of the American Chemical Society and a member of the ACS Medicinal Chemistry Hall of Fame. He is an author on over 100 peer reviewed publications and inventor on over 40 patent applications. The adviser/operating affiliation is distinct from a statutory directorship or personal cash check.

Oliver Jarvis is a published Biotech Investment Manager with the Parkinson’s Research Ventures programme. Own biography: Oliver brings expertise in the commercial side of Biotech. Before joining Parkinson's Research Ventures, he worked in corporate development at Vaccitech, a NASDAQ traded biotech developing immunotherapies for oncology, infectious disease, and autoimmunity. Prior to this, he worked across biomedical commercialisation and government in New Zealand. The adviser/operating affiliation is distinct from a statutory directorship or personal cash check.

Iwona Ziomkiewicz is a published Drug Discovery Manager (Biology) with the Parkinson’s Research Ventures programme. Own biography: Iwona joined Parkinson’s UK in September 2022 as a Drug Discovery Manager representing the biology specialisation. She brings experience in cell-based assays for in vitro pharmacology and translational research of small and large molecules. Iwona has a strong background in mechanistic biology with a track record of working in oncology and neuroscience therapeutic areas. The adviser/operating affiliation is distinct from a statutory directorship or personal cash check.

Ana Mora is a published Clinical Studies Portfolio Manager with the Parkinson’s Research Ventures programme. Own biography: Ana holds a PhD in Neuroscience from University College London and has nearly 20 years clinical trials experience across all phases, holding senior operational roles. Ana has a track record of fostering collaborations between the NHS, academia, and industry to deliver world-class, evidence-based medical research focused on patient benefit. The adviser/operating affiliation is distinct from a statutory directorship or personal cash check.

David Shaw is a published Drug Discovery Manager (Chemistry) with the Parkinson’s Research Ventures programme. Own biography: David has 15 years of drug discovery experience with GSK, Pfizer, Vertex and MSD respectively. He is a key contributor and leader for multiple successful clinical POCs and pivotal Phase III trials, alongside establishing, leadership and development of medicinal chemistry and cross functional teams. The adviser/operating affiliation is distinct from a statutory directorship or personal cash check.

Michael Hurley is a published Senior Drug Discovery Manager (Biology) with the Parkinson’s Research Ventures programme. Own biography: Michael is a neuropharmacologist with over 25 years of experience researching the cause and treatment of Parkinson’s disease. He has extensive neuropathological and behavioural expertise in the use of in vivo models of Parkinson’s disease to study molecular mechanisms involved in neurodegeneration and neuroinflammation. The adviser/operating affiliation is distinct from a statutory directorship or personal cash check.

Lynsey Bilsland is a published Managing Director of Parkinson's Research Ventures with the Parkinson’s Research Ventures programme. Own biography: Previously Head of Mental Health Innovation at Wellcome, Lynsey brings over 15 years experience in healthcare investment supporting development of interventions for patient benefit. Lynsey has expertise in neuroscience, pharmacology and in vitro and in vivo models of neurodegeneration. The adviser/operating affiliation is distinct from a statutory directorship or personal cash check.

Juliet Tizzard led Parkinson’s UK externalrelations untilMay2026, explicitly dated in the own2025annualreport published2026 and corroborated by her own departure announcement. A charityMay10,2022 announcement says she would join thatsummer, initially titled DirectorExternalAffairsAndCommunications. Earlier professional roles were HealthResearchAuthority DirectorPolicyAndPartnerships, HumanFertilisationAndEmbryologyAuthority and BritishMedicalAssociation policy/communications. She is not counted as a current executive; precise employment start/endday is unknown.

Matthew Durdy is former vicechair/trustee of Parkinson’s UK, leaving the board inMarch2026 as the own2025annualreport released2026 explicitly states. He also served as director/chair of its separate research subsidiary; CompaniesHouse confirms subsidiary directorshipMay30,2023 toMarch25,2026. The exact subsidiary resignationday is not automatically assigned to the charity trustee role. His current own CellAndGeneTherapyCatapult biography identifies him as chiefexecutive and foundingteam member2012, with Oxfordbiology and ChicagoMBA education, and a prior career in investment banking, venture capital and biotechnology business. No personal check is inferred.

Birgitte, Duchess of Gloucester, is the formal royal patron of Parkinson’s UK since1996, confirmed by the charity and the RoyalFamily’s current own biography. RoyalUK identifies her full birthname BirgitteEvaVanDeursHenriksen and her charity/patronage work. This honorary association is distinct from statutory charity governance, employment and personal investment. Exact patron appointment day is not disclosed.

Jane Asher is Parkinson’s UK’s formal honorary president, first appointedFebruary2007 according to its own president biography. The same page confirms her term continues through the end of2026. She is an actor, author and entrepreneur; her president role supports the charity’s Parkinson’s community and advocacy work, not an executive job or personal financing. Precise starting day is undisclosed.

Judeth Neville is company secretary of Parkinson’s UK and its separate Parkinson’s Research Ventures subsidiary, each filed appointmentFebruary5,2025. Her own RennieGrovePeaceHospiceCare trustee biography confirms Parkinson’s UK’s current secretary position and a career beginning in corporate law, followed by charity legal/governance roles including Oxfam and the RoyalHorticulturalSociety. Her genuine own hospice portrait is published under a filename spellingJudith; the named biography establishes exactJudeth identity. No full hidden staff roster or investment ticket is inferred.

Kristina Murrin CBE joined Parkinson’s UK’s statutoryboard on September1,2026 according to CompaniesHouse. Its June3,2026 announcement names her chair-elect, joining trustees inSeptember and succeeding GaryShaughnessy inOctober2026 without an exact handoverday. The same own biography describes her recent role as chiefexecutive of TheKing’sFoundation and earlier senioradviser atNumber10, with experience in socialinnovation and leadership. Her father lived withParkinson’s for30years. A completedOctober chair handover is not presumed from a plannedmonth-onlyannouncement.

Parkinson’s Research Ventures Limited is the separate wholly owned drug-development investment subsidiary of Parkinson’s UK, exact active UK company11228595 incorporatedFebruary27,2018. The public Parkinson’s Research Ventures programme was formerly Parkinson’s Virtual Biotech and is led by Parkinson’s UK in partnership with the separately incorporated Parkinson’s Foundation. It supports pre-seed, seed and SeriesA neuroscience development projects and clinical studies aimed at disease modification and unmet Parkinson’s symptoms. Funding arrangements include grants, company investments and convertible research loans; a published scientific portfolio is not necessarily a list of equity holdings. The official programme uses Parkinson’s UK’s authentic shared parent brand/logo; an independent unit logo was not verified. May2026 literature says overGBP33M committed across the programme, not a closed LP fund or verified amount paid to companies. Annual2025 accounts explicitly identify convertible-loan debtors funding EndLyzTherapeuticsInc through this subsidiary; group EndLyz equity and subsidiary loan arrangements must remain distinct. The charity’s24.203M intercompany loan receivable is parent-to-subsidiary financing, not EndLyz financing; EndLyz’s720K reported fairvalue is not a new paid ticket. The subsidiary has ten current statutory officers, seven named operating research/investment staff and seven external drug-discovery advisers; advisory/operating roles do not imply statutory directorship. IanGarland is chair fromFebruary2026 with exact chairday undisclosed; CompaniesHouse separately confirms his statutory director appointmentMay30,2023. MatthewDurdy resigned statutorydirectorshipMarch25,2026 and is separately marked former. Experimental research outcomes are not independent clinical efficacy or marketing approval claims.

Sonia Gandhi is listed by Parkinson’s UK as Professor Sonia Gandhi. Own published biography: Professor Sonia Gandhi Photo credit: Dave Guttridge I was delighted to be appointed in 2026 as both a Parkinson’s UK trustee and as a director of the charity’s drug development and discovery programme, Parkinson’s Research Ventures. I am a Deputy Research Director at The Francis Crick Institute and a Professor of Neurology at UCL where I lead a neuroscience research programme focused on Parkinson’s, driven by patient involvement, and aiming to discover new treatments for the condition. Throughout my career, I have sought to understand the molecular causes of Parkinson’s and have been involved in studies exploring the potential of disease modifying therapies and developing  precision medicine approaches. I'm excited to be helping to shape the future of Parkinson's UK to provide the best possible support to the Parkinson’s community and to play a role in developing Parkinson's Research Ventures' portfolio of new drugs.

Sangeeta Kulkarni is listed by Parkinson’s UK as Dr Sangeeta Kulkarni. Own published biography: Dr Sangeeta Kulkarni I was honoured to be appointed as a trustee in December 2024. I am a consultant geriatrician based in Gloucestershire with over a decade of experience in the care of older adults, including those living with Parkinson’s. I hope to contribute to the charity’s mission by offering a clinical perspective on key decisions, supporting the development of educational programs, and advocating for improved access to specialist care. My role as a clinical specialist has given me an insight into the complexities of symptom management, the importance of multidisciplinary care, and the need for continuous innovation in treatments and support services. I am particularly interested in enhancing awareness and education around non-motor symptoms of Parkinson’s, such as cognitive decline, sleep disturbances, frailty, multiple coexisting health conditions and mental health challenges. These symptoms can often be overlooked but have a profound effect on an individual’s well-being. I believe that collaboration between medical professionals, researchers, policymakers, and patient communities is essential in driving progress. I am excited to contribute to the charity’s initiatives, ensuring that every person with Parkinson’s has access to the best possible care, support, and information. Watch Sangeeta's chat with Gary Shaughnessy (our Chair) on YouTube to find out more about her interests, background and why she became a Parkinson's UK trustee. Companies House spells the same trustee legal name Sangita Sachin Kulkarni; the statutorydirector appointmentFebruary5,2025 is distinct from the biography’s December2024 trusteejoining statement.

Pamela Harding is listed by Parkinson’s UK as Pamela Harding. Own published biography: Pamela Harding I became a trustee and Chair of the Board’s People Committee in 2025. My professional and volunteer work is driven by a desire to serve and benefit individuals and societies. The work that Parkinson's UK does is close to my heart because a close relative has Parkinson's. As an experienced senior HR professional, I've successfully developed and led many people-related initiatives that have improved organisations’ effectiveness. I also have expertise in organisational design and understanding how the right technology, processes, people, culture, and resources contribute to achieving the best results.

Peter Miller is listed by Parkinson’s UK as Peter Miller. Own published biography: Peter Miller I am delighted to have been elected a Trustee of Parkinson’s UK for a second time as I have a deep personal commitment to improve the lives of those affected by Parkinson’s. My wife’s diagnosis in 2014, resulted in my involvement in advocacy and research within the Parkinson’s community locally and nationally. I enjoyed a career in international sales and marketing including leadership roles at HP and Pearson, giving me experience in lobbying, governance and stakeholder engagement. After retiring in 2017, I dedicated my time to volunteering for the NHS, Parkinson’s UK, and other charities. I served as a Trustee of Parkinson’s UK from 2019 to 2023, representing the Parkinson’s community in England. In 2018, my wife and I were co-founders of Fighting Fit, a small charity delivering residential wellbeing courses for those with early-stage Parkinson’s. At the end of 2023, I was diagnosed with multiple myeloma (an incurable, but treatable, cancer of the bone marrow) and as a result stepped back during chemo treatment but I am currently in remission and ready to get back to work. I am passionate about championing the patient voice, tackling healthcare inequality, and supporting those with complex and advanced Parkinson’s. I relish the opportunity to support the future development of the charity.

Katrina Green is listed by Parkinson’s UK as Katrina Green. Own published biography: Katrina Green I was appointed trustee and Finance Trustee in 2020. My dad was diagnosed with Parkinson’s in 2017 after experiencing symptoms for over a decade, so that’s where my motivation comes from. In my day job I work in corporate finance for an insurance company and I’m a Chartered Financial Analyst (CFA) Charterholder. Outside of work and Parkinson’s UK, I love to travel and play an active role in my community in North London. My experience in finance means I’m passionate about making the most of every penny Parkinson’s UK receives. I want us to find a cure and in the meantime make life better for people with Parkinson’s, and their family, friends and carers. Watch Katrina's chat with Gary Shaughnessy (our Chair) on YouTube to find out more about her interests, background and why she became a Parkinson's UK trustee.

Jane Burston is listed by Parkinson’s UK as Jane Burston OBE. Own published biography: Jane Burston OBE In my day job, I run a charity of a similar size. I bring experience of what others in the charity sector are doing, so we can keep up to date. I also have a lot of fundraising experience, having raised over £150m for my organisation in the last 4 years. Previously, I was head of a department of a large science lab, responsible for managing £18m of scientific research each year, so I can also contribute to discussions about research for new treatments. I’m involved with Parkinson’s UK because my dad was diagnosed at age 40. I used to run a lot of marathons for Parkinson’s and have met some fantastic people on sponsored walks who are now firm friends. Because of my dad and my younger friends with Parkinson’s, I think a lot about how Parkinson’s UK can support people of working age with Parkinson’s and the challenges they face, such as caring for younger families. I love volunteering for Parkinson’s UK and hope I get re-elected so I can continue to contribute to making life better for everyone affected. Watch Jane's chat with Gary Shaughnessy (our Chair) on YouTube to find out more about her interests, background and why she became a Parkinson's UK trustee.

Janet Shipton is listed by Parkinson’s UK as Janet Shipton. Own published biography: Janet Shipton I am delighted to be elected as a Trustee for Parkinson’s UK, and feel passionate about using my voice to represent those that don’t have one. With over 25 years of project and design management experience in retail, manufacturing, research, and design, I completed a PhD at Sheffield Hallam University in 2007. I also set up and managed a deli, my own design business, and community art groups. I was a Trustee of two community charities and co-founded a youth club and a social dining club for the elderly. Diagnosed with Younger Onset Parkinson’s Disease in 2018 at the age of 47, I redirected my energy to being a Parkinson’s advocate and artist. As the co-founder of the award-winning Parkinson’s theatre group "Parky Players" in 2020, I have been the lead fundraiser and co-producer for their three theatre productions that toured the UK, including award-winning and five-star runs at the Edinburgh Fringe. I live with my partner and our two dogs, and enjoy performing stand-up comedy, and singing and playing keyboards. I also enjoy boxing training and walking football. I’m a volunteer for the Mansfield Parkinson’s Support Group.

Kate Platts is listed by Parkinson’s UK as Kate Platts. Own published biography: Kate Platts I was honoured to be appointed in 2023 to represent Members on the Board of Trustees for Parkinson’s UK and look forward to helping shape and ensure the delivery of all of the charity’s strategic aims. As the finance contact for the Sheffield Support Group of volunteers, I work proactively to support and create a community for those with Parkinson's locally. I also enjoy supporting the regional fundraising activities. As a Fellow of The Institute of Chartered Accountants in England and Wales and the Finance Director for a national social care sector charity, I believe I can bring my financial skills and acumen to be a highly effective member of the Board and ensure we have the funds to invest in Parkinson’s UK. I will use my experiences of postdoctoral work in cancer research within the NHS and university settings to contribute effectively at meetings, supporting the provision of excellent health care and investing in research for new treatments. In my spare time, I love nothing more than being with my family, keeping fit, going to the theatre and reading.

Tom Mortier is published in PMV’s current public directory as Head of Energy Transition; PMV Fund Management affiliation (related manager). This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Tom Pittevils is published in PMV’s current public directory as Accountant. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Veerle Gysemberg is published in PMV’s current public directory as HR Officer. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Veerle Van den Acker is published in PMV’s current public directory as Fund & Loan Administrator. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Vincent Hebbelynck is published in PMV’s current public directory as Head of Unit Expert. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Ward Stynen is published in PMV’s current public directory as Investment manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Werner Decrem is published in PMV’s current public directory as Executive Committee Member - Infrastructure & Real Estate; PMV Fund Management affiliation (related manager). This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Werner Elpers is published in PMV’s current public directory as Senior credit analyst. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

William Olyslager is published in PMV’s current public directory as Investment manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Wim D’Hoe is published in PMV’s current public directory as File manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Wouter Winnen is published in PMV’s current public directory as Head of Fund of Funds. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Xuefei Liu is published in PMV’s current public directory as Investment analyst. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Yves Slachmuylders is published in PMV’s current public directory as Investment Director. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Ian Garland is listed by Parkinson’s UK as Ian Garland. Own published biography: Ian Garland I became a trustee of Parkinson’s UK in 2025 and have been an Independent Director of the Parkinson’s Research Ventures Board since 2023. I worked in the pharmaceutical sector for almost 20 years, with the majority of that time as Chief Executive. I have experience across all aspects of drug development and commercialisation in both the UK and US. The companies I have worked for have included those marketing existing treatments and others developing potential new treatments for Parkinson’s Disease. I started my career in finance, qualifying as a Chartered Accountant. During my time in the accounting profession, I began focusing on the pharmaceutical sector and became passionate about improving the lives of people facing untreatable or poorly treated diseases. I left the accounting profession and moved into the pharmaceutical sector to make a tangible contribution to finding new and improved treatments. I am excited to be able to bring my experiences and skills to Parkinson’s UK and the PRV Board and improving the lives of people with Parkinson’s. Outside of work, when not caring for my elderly parents, I enjoy spending time with my family, working in my garden, travelling, walking and playing golf.

Thomas Rossaert is published in PMV’s current public directory as Investment manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Thomas Ykman is published in PMV’s current public directory as Investment manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.